NCT00232635View on ClinicalTrials.gov

A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT

PHASE2CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG

A-60444

Trial Locations (1)

Unknown

Stephen MacKinnon, London

Sponsors

Lead Sponsor

Arrow Therapeutics

All Listed Sponsors

lead

Arrow Therapeutics

INDUSTRY

NCT00232635 - A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT | Biotech Hunter | Biotech Hunter